Despite its appeal, to date only one selective and highly potent small molecule Wee1 inhibitor, AZD1775 (also known as Adavosertib or MK-1775) (39), has been widely reported and is being evaluated against various advanced cancers in phase I/II clinical trials either as a monotherapy (40–42) or in combination with other chemotherapies (40, 43, 44). The gene discussed is WEE1; the disease is cancer.